All posts by: Michael Zand

Pfizer launches a gene therapy study for Duchenne MD; Amgen, NEA back real-world drug data software company – Endpoints News

Further Evidence that Immunotherapy Provides a Longterm Survival Benefit for Lung Cancer Patients – Drug Discovery & Development

Drug Discovery & DevelopmentFurther Evidence that Immunotherapy Provides a Longterm Survival Benefit for Lung Cancer PatientsDrug Discovery & DevelopmentFurther evidence that immunotherapy provides long-term survival benefit for patients with lung canc… Continue reading

The Market and Potential for CRISPR/Cas9 Gene Editing 2017-2023 – PR Newswire (press release)

Interesting EngineeringThe Market and Potential for CRISPR/Cas9 Gene Editing 2017-2023PR Newswire (press release)In 2018, more than 30 players participate in this market, from large multinational corporations to small, niche life sciences companies. Ke… Continue reading

The Market and Potential for CRISPR/Cas9 Gene Editing 2017-2023 – PR Newswire (press release)

Interesting EngineeringThe Market and Potential for CRISPR/Cas9 Gene Editing 2017-2023PR Newswire (press release)In 2018, more than 30 players participate in this market, from large multinational corporations to small, niche life sciences companies. Ke… Continue reading

Researchers optimize lung stem cell engineering process – Phys.Org

Researchers optimize lung stem cell engineering processPhys.OrgThe Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center has engineered two new categories of lung epithelial cells in vitro using pluripotent stem cells. … Continue reading

Scientists Edit Thousands of Genes at Once With Upgraded CRISPR – Gizmodo UK

Scientists Edit Thousands of Genes at Once With Upgraded CRISPRGizmodo UKWhen the gene-editing technology CRISPR first made a splash back in 2012, it foretold a future in which curing diseases might simply involve snipping out problematic bits of genet… Continue reading